Abicipar Pegol In Patients with Neovascular Age-related Macular Degeneration

What we are studying

Assess safety and efficacy of abicipar compared with ranibizumab in treatment naive patients with neovazcular AMD.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 50+

Eligibility Criteria

  • Treatment naive patients with neovascular AMD
  • BCVA 20/40 to 20/320 in study eye
  • 20/200 or better in non study eye
  • Uncontrolled glaucoma
  • History of uveitis

What is involved

  • Monthly visits
  • Labs
  • Ocular photography
  • Labs
  • Questionnaires



Contact Information

Study Coordinator
Joan Fish

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.